User:Werldwayd/Articles-Test197

This is a Wikipedia user page.
This is not an encyclopedia article or the talk page for an encyclopedia article. If you find this page on any site other than Wikipedia, you are viewing a mirror site. Be aware that the page may be outdated and that the user in whose space this page is located may have no personal affiliation with any site other than Wikipedia. The original page is located at https://en.wikipedia.org/wiki/User:Werldwayd/Articles-Test197.

This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft.

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL
Easy tools: Citation bot (help) | Advanced: Fix bare URLs
This page was last edited by Werldwayd (talk | contribs) 4 years ago. (Update timer)

Finished writing a draft article? Are you ready to request an experienced editor review it for possible inclusion in Wikipedia? Submit your draft for review!

This is strictly a personal page for Werldwayd for follow-up on articles I am developing for follow up and eventual publication in Wikipedia Main

Hagop M. Kantarjian is an MD and professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he is also the Samsung Distinguished Leukemia Chair in Cancer Medicine. He is also a non-resident fellow in health policy at the Rice University Baker Institute.

Awards

Doctor Kantarjian has received several prestigious honours and awards including:

2008: John Mendelsohn Lifetime Scientific Achievement Award
2012: 37th Jeffrey A Gottlieb Memorial Award
2013: Joseph H. Burchenal Memorial Award
2014: Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer
2014: Top Castle Connolly National Physician of the Year Award for Lifetime Achievement (2014). Doctor Kantarjian’s research focuses on translational-clinical developmental therapeutics in leukemia. In the past three decades, he has made several contributions that improved prognosis and survival in patients with chronic myeloid leukemia (tyrosine kinase inhibitors, e.g. imatinib, dasatinib, nilotinib, bosutinib which improved the 10-year survival from 20% to 90%), in acute lymphocytic leukemia (HPER-CVAD regimen and its derivatives which improved cure rates from 20% to 60+%), the discovery of decitabine for the treatment of myelodysplastic syndrome, and of clofarabine for the treatment of leukemias, among others. His research and collaborations were the basis for the FDA approvals of over 20 drugs in leukemia. He is an author on over 1,800 peer-reviewed publications.